R&D Blueprint
The R&D Blueprint is a global strategy and preparedness plan that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large scale crises. With WHO as convener, the broad global coalition of experts who have contributed to the Blueprint come from medical, scientific and regulatory backgrounds. WHO Member States welcomed the development of the Blueprint at the World Health Assembly in May 2016.

R&D Blueprint and Zika

Zika virus is a mosquito-borne flavivirus that was first identified in Uganda in 1947 in monkeys. It was later identified in humans in 1952 in Uganda and the United Republic of Tanzania.

Outbreaks of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific. From the 1960s to 1980s, rare sporadic cases of human infections were found across Africa and Asia, typically accompanied by mild illness. The first recorded outbreak of Zika virus disease was reported from the Island of Yap (Federated States of Micronesia) in 2007. This was followed by a large outbreak of Zika virus infection in French Polynesia in 2013 and other countries and territories in the Pacific. In March 2015, Brazil reported a large outbreak of rash illness, soon identified as Zika virus infection, and in July 2015, found to be associated with Guillain-Barré syndrome.  In October 2015, Brazil reported an association between Zika virus infection and microcephaly. Outbreaks and evidence of transmission soon appeared throughout the Americas, Africa, and other regions of the world.

 

Target product profiles (TPPs)

This TPP describes the preferred and minimal product characteristics for vaccines aimed at protecting against congenital ZIKV syndrome during emergency...

From 1 January 2007 to 16 March 2016, Zika virus (ZIKV) transmission was documented in a total of 59 countries and territories. The geographical distribution...

Zika virus vaccine product development

 

Documents on regulatory expectations of Zika vaccines

Vaccine development technology roadmaps produced by the World Health Organization (WHO) aim to provide a strategic framework underpinning priority activities...

This TPP describes the preferred and minimal product characteristics for vaccines aimed at protecting against congenital ZIKV syndrome during emergency...

Pipeline

As part of the broader response to Zika WHO has initiated an emergency research and development plan. This is the first effort following the West-Africa...